Synapse Open Synapse
Biology

Genmab soars to record highs after cancer drug succeeds in key trial

BioPharma Dive · · 2 min read

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.

Latest from BioPharma Dive